Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects

• Main Authors: Shumao Ni (Author), Sheng Ma (Author), Yingying Yu (Author), Zhenwen Yu (Author), Yujia Zhu (Author), Xiaofen Sun (Author), Lin Li (Author), Caixia Sun (Author), Hui Wang (Author), Peng Peng (Author), Zheming Gu (Author), Hua Zhang (Author), Frank Wu (Author), Liyan Miao (Author), Jean Fan (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background and Objective Tinengotinib, a novel multi-target small molecule kinase inhibitor, is currently undergoing phase II clinical trial in the USA and China. The purpose of this open-label study was to investigate the absorption, metabolism, and excretion of [14C]tinengotinib following...